Close

Printed from https://fyi.org.nz/user/mary_hobbit on May 12, 2025 07:13

FYI

Menu Close
Sign in or sign up
  • Make a request
  • Browse requests
  • View authorities
  • Help

Track this person

Follow
RSS icon RSS feed of updates

On this page

Official Information requests
Annotations

Mary Hobbit

Joined FYI in 2021

Send message to Mary Hobbit

Sign in to change password, subscriptions and more (Mary Hobbit only)

This person's 5 Official Information requests

COVID-19 Vaccine Technical Advisory Group - Frequency of Governance Meetings and Latest Minutes
Response by Ministry of Health to Mary Hobbit on March 23, 2022.
Awaiting classification.
Kia ora Mary Please find attached a letter regarding your request for information.  Ngā mihi   OIA Services Team   [1]Ministry of Health inf...
Novavax Rollout in New Zealand
Response by Ministry of Health to Mary Hobbit on February 15, 2022.
Long overdue.
Kia ora Megan,   Thank you for your email. You asked:   - What are the timeframes Cabinet is working to in order to provide a decision on the...
Novavax Vaccine and Information on Cabinet Approval
Response by Ministry of Health to Mary Hobbit on January 28, 2022.
Awaiting classification.
Kia ora Mary/Megan, Thank you for your email.  Novavax started their rolling application to Medsafe in August and the data has been under evaluation...
Janssen Vaccine
Response by Ministry of Health to Mary Hobbit on November 25, 2021.
Awaiting classification.
Kia ora Mary,   Thank you for your email. As you know, the Johnson & Johnson (Janssen) vaccine has received provisional approval from Medsafe. How...
Other vaccines
Response by Ministry of Health to Mary Hobbit on November 23, 2021.
Awaiting classification.
Kia ora Mary,   Thank you for your query regarding the Novavax vaccine. This vaccine is not currently approved for use in New Zealand.   Medsa...

This person's annotations

None made.

  • Powered by Alaveteli
  • Contact us
  • Help
  • Privacy and cookies
  • API
  • @FYI_NZ
  • Supported by
X Paste this link into emails, tweets, and anywhere else: